The ASPC 2021 Virtual Summit on CVD Prevention will aim to bring attendees the same learning and connection they find at our face-to-face meeting.  This year we will emphasize inclusiveness and the care of one and all at risk for cardiovascular disease. The program will provide cutting-edge lectures, lively debates, and practical applications. We will explore the broad spectrum of preventive cardiology led by world-renowned experts in the field. It will cover topics such as Emerging Therapies for Lipid Management, CAC vs. biomarkers, Chest pain and Imaging, Prevention of Heart Failure, Atrial Fibrillation, PAD evaluation, treatment, and management, practical application of New Prevention Therapies, CVD prevention in Special populations, and more.

TARGETED AUDIENCE

This activity is designed for an audience of physicians, physician assistants, nurses, pharmacists, dieticians, research scientists and other healthcare professionals.

EDUCATIONAL OBJECTIVES

Upon completion of the educational activity, participants should be able to:

• Evaluate emerging lipid therapies and assess their ASCVD risk reduction while implementing this knowledge into clinical practice.
• Evaluate the literature involving CVD risk in CKD and DM patients in an effort to implement this knowledge into clinical practice.
• Compare the literature involving biomarkers versus CAC testing in ASCVD prevention and implement this knowledge into clinical practice.
• Assess and evaluate current ACS treatment strategies in patients with COVID-19 and implement into daily management.
• Evaluate the latest literature to determine the pretest probability (PTP) of coronary artery disease (CAD) in symptomatic patients and how to proceed with test selection and implement this knowledge into clinical practice.
• Evaluate the literature involving diets to reduce cardiovascular risk and implement this knowledge into clinical practice.
• Discuss the contribution of adverse social determinants of Health and CV outcomes, demonstrate the pernicious influence of structural barriers that impede equitable health, explore proactive steps to narrow disparities and achieve health equity.
• Evaluate the literature involving lifestyle modifications to prevent heart failure and implement this knowledge into clinical practice.
• Understand strategies to prevent atrial fibrillation and implement this knowledge into clinical practice.
• Evaluate the medical and lifestyle management of PAD that incorporate therapies to improve functional outcomes, reduce adverse cardiovascular, and limb events.
• Review the rationale and Results of VITAL Trial, describe recent update of Metanalysis of Vitamin D, Omega-3s and these outcomes, and discuss which patients are more or less likely to benefit from supplementation.
• Understand implementation strategies to improve care, prevent heart disease, and implement this knowledge into clinical practice.
• Evaluate best practices in telemedicine, including proper billing, and implement this knowledge into clinical practice.
  Evaluate the literature involving transgender patients, CVD, and hormone replacement therapy and implementing this knowledge into clinical practice.
• Discuss current strategies to prevent heart disease, stroke, and diabetes through proper diet and accessibility and implement this knowledge into clinical practice.
• Evaluate the literature involving the unmet needs in the use of statins and aspirin in PLWHIV and review the incompleteness of the current guideline to implement any prevention knowledge into clinical practice.
• Critically evaluate the data relating to Cardiovascular Risk among Men and Women of Asian Ancestry.

ACCREDITATION

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.